Please use this identifier to cite or link to this item:
Title: Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
Author: Marques, Joana
Valle Delgado, Juan José
Urbán, Patricia
Baró, Elisabet
Prohens, Rafel
Mayor Aparicio, Alfredo Gabriel
Cisteró, Pau
Delves, Michael
Sinden, Robert E.
Grandfils, Christian
Paz, José L. de
García Salcedo, José A.
Fernàndez Busquets, Xavier
Keywords: Malària
Issue Date: Feb-2017
Publisher: Elsevier
Abstract: The adaptation of existing antimalarial nanocarriers to new Plasmodium stages, drugs, targeting molecules, or encapsulating structures is a strategy that can provide new nanotechnology-based, cost-efficient therapies against malaria. We have explored the modification of different liposome prototypes that had been developed in our group for the targeted delivery of antimalarial drugs to Plasmodium-infected red blood cells (pRBCs). These new models include: (i) immunoliposome-mediated release of new lipid-based antimalarials; (ii) liposomes targeted to pRBCs with covalently linked heparin to reduce anticoagulation risks; (iii) adaptation of heparin to pRBC targeting of chitosan nanoparticles; (iv) use of heparin for the targeting of Plasmodium stages in the mosquito vector; and (v) use of the non-anticoagulant glycosaminoglycan chondroitin 4-sulfate as a heparin surrogate for pRBC targeting. The results presented indicate that the tuning of existing nanovessels to new malaria-related targets is a valid low-cost alternative to the de novo development of targeted nanosystems.
Note: Reproducció del document publicat a:
It is part of: Nanomedicine: Nanotechnology, Biology and Medicine, 2017, vol. 13, num. 2, p. 515-525
Related resource:
ISSN: 1549-9634
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
MarquesJ_Nanomedicine_2017.pdf1.42 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons